Completed PHASE3 INTERVENTIONAL 2-arm NCT01614886

Randomized, Double-blind Study to Evaluate the Tolerability of 2 Different Titration Methods of Rivastigmine Patch in AD Patients (MMSE 10-20)

A 24-week, Multicenter, Parallel-group, Randomized,Double-blind Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Methods of Rivastigmine Patch (ENA713D/ONO-2540) in Patients With Mild to Moderate Alzheimer's Disease (MMSE 10-20)

Sponsor: Novartis Pharmaceuticals

Conditions Alzheimer's Disease

Interventions Active Comparator ENA713

Updated 6 times since 2017 Last updated: Jun 30, 2016 Started: Jul 31, 2012 Primary completion: May 31, 2014 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Alzheimer's Disease, this trial is completed. The trial is conducted by Novartis Pharmaceuticals and has accumulated 6 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jul 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals
Ono Pharmaceutical Co. Ltd

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Akita, Japan , Anjo, Japan , Azumino, Japan , Bunkyo-ku, Japan , Chiba, Japan , Fujioka, Japan , Fukuoka, Japan , Hachiōji, Japan , Hiroshima, Japan , Kamakura, Japan and 33 more locations